MARKET

FMTX

FMTX

Forma Therapeutics Holdings, Inc.,
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.84
-0.46
-1.97%
After Hours: 22.84 0 0.00% 16:00 09/21 EDT
OPEN
23.63
PREV CLOSE
23.30
HIGH
24.63
LOW
22.78
VOLUME
355.05K
TURNOVER
--
52 WEEK HIGH
56.33
52 WEEK LOW
21.04
MARKET CAP
1.08B
P/E (TTM)
-7.5432
1D
5D
1M
3M
1Y
5Y
Forma Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., September 17, 2021--Forma Therapeutics to Participate in Upcoming Investor Conferences.
Business Wire · 4d ago
HC Wainwright & Co. Maintains Buy on Forma Therapeutics Hldgs, Lowers Price Target to $53
HC Wainwright & Co. analyst Robert Burns maintains Forma Therapeutics Hldgs (NASDAQ:FMTX) with a Buy and lowers the price target from $55 to $53.
Benzinga · 08/17 10:27
--HC Wainwright Adjusts Price Target on Forma Therapeutics Holdings to $53 From $55, Keeps Buy Rating
MT Newswires · 08/17 08:05
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
Forma Therapeutics Hldgs Q2 EPS $(0.92) Misses $(0.79) Estimate
Forma Therapeutics Hldgs (NASDAQ:FMTX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.79) by 16.46 percent. This is a 79.91 percent increase over losses of $(4.58) per
Benzinga · 08/13 11:10
Forma Therapeutics' Q2 Loss Narrows, Operating Expenses Rise
MT Newswires · 08/13 07:37
Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
WATERTOWN, Mass., August 06, 2021--Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
Business Wire · 08/06 11:05
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2021
 
Benzinga · 08/02 14:23
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FMTX. Analyze the recent business situations of Forma Therapeutics Holdings, Inc., through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FMTX stock price target is 56.29 with a high estimate of 68.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 41.47M
% Owned: 87.52%
Shares Outstanding: 47.39M
TypeInstitutionsShares
Increased
35
1.76M
New
13
415.06K
Decreased
18
676.24K
Sold Out
18
1.66M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.34%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Non-Executive Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Director
Frank Lee
Chief Financial Officer/Senior Vice President
Todd Shegog
Chief Human Resource Officer/Senior Vice President
Mary Wadlinger
Senior Vice President/Chief Scientific Officer
David Cook
Senior Vice President/General Counsel/Secretary
Jeannette Potts
Senior Vice President
Patrick Kelly
Chief Technology Officer
John Bishop
Independent Director
Timothy Clackson
Independent Director
Marsha Fanucci
Independent Director
Wayne Frederick
Independent Director
Peter Kolchinsky
Independent Director
Selwyn Vickers
Independent Director
Thomas Wiggans
No Data
  • All
  • Financials
  • Insiders
More
About FMTX
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with rare hematologic diseases and cancers. Its pipeline consists of seven product candidates, two of which it is pursuing as core product candidates for development: FT-4202 for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its other product candidate includes FT-2102 (Olutasidenib), FT-8225, FT-4101, CC-95775 and BI-1701963. FT-4202 is an oral, once-daily, potentially disease-modifying therapy. FT-4202 is a potent activator of pyruvate kinase-R (PKR), designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. FT-7051, is a potent and selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300).

Webull offers kinds of Forma Therapeutics Holdings Inc stock information, including NASDAQ:FMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FMTX stock methods without spending real money on the virtual paper trading platform.